What is VariZIG?
VariZIG is approved by the U.S.(FDA) for (PEP) of primary (VZV) (also called varicella or chicken pox) in people at high-risk for severe disease. People at high risk of severe varicella include pregnant women, premature infants, and children and adults who are . VariZIG is intended to reduce the severity of varicella if infection occurs.
Primary VZV infection can be an What is an Opportunistic Infection? fact sheet.(OI) of HIV. An OI is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as people with HIV—than in people with healthy immune systems. To learn more about opportunistic infections, read the HIVinfo
How is VariZIG used in people with HIV?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV and the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children include recommendations on the use of VariZIG for post-exposure prophylaxis (PEP) of primary VZV infection in people with HIV.
The recommended uses may not always be consistent with FDA-approved uses of VariZIG. See the Adult and Pediatric Opportunistic Infection Guidelines for complete information on recommended uses of VariZIG in adults and children with HIV. VariZIG may have other recommended uses not listed above.
What should I tell my health care provider before receiving VariZIG?
Before receiving VariZIG, tell your health care provider:
- If you are allergic to VariZIG or any other medicines.
- About any medical conditions you have or have had, particularly:
- If you have ever had an anaphylactic reaction or a severe systemic allergic reaction to human immune globulin preparations.
- If you are deficient in immunoglobulin A (IgA).
- About anything that may prevent you from receiving medicine by injection.
- If you are pregnant or plan to become pregnant. Talk to your health care provider about the risks and benefits of receiving VariZIG during pregnancy. The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV may include other recommendations on the use of VariZIG during pregnancy. Please refer to these guidelines for additional information.
- If you are breast/chestfeeding or plan to breast/chestfeed. For people with HIV in the United States, the Guideline recommends speaking with your health care provider to discuss options for feeding your baby. People with suppressed viral load have a less than 1% chance of transmitting HIV to their baby via their own milk.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. VariZIG may affect the way other medicines or products work, and other medicines or products may affect how VariZIG works. Ask your health care provider if there are interactions between VariZIG and the medicines you take.
Ask your health care provider about possible side effects from VariZIG. Your health care provider will tell you what to do if you have side effects.
How is VariZIG given?
VariZIG dosing is based on a person’s weight. Theis divided and given by injection. VariZIG is given as soon as possible after exposure to VZV, ideally within 96 hours of exposure for the greatest effectiveness. A person re-exposed to VZV more than 3 weeks after receiving VariZIG may get a second dose of the drug.
Where can I find more information about VariZIG?
- Recommendations on the uses of VariZIG in people with HIV, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.
- This Patient Version drug summary is based on the following FDA label(s): Injection (sterile solution). The Patient Counseling Information section of the label includes information for people receiving VariZIG.
- VariZIG-related research studies, from ClinicalTrials.gov. (The ClinicalTrials.gov search can be modified so that you can get results that better match your interests. To learn more about the ClinicalTrials.gov search features, please see How to Search.)
Last Reviewed: April 13, 2021